Mr. James Lee reports

HEALWELL AI ANNOUNCES VOTING RESULTS OF 2025 AGM

Healwell AI Inc. has released the voting results from its annual general meeting of the shareholders of the company held on June 30, 2025. Shareholders representing approximately 71 per cent of the votes attributable to Healwell's outstanding shares attended the meeting in person or were represented by proxy.

All matters of business set out in the company's management information circular dated May 23, 2025, were passed at the meeting, including: fixing the number of directors at six, re-electing the six incumbent directors and appointing Deloitte LLP as auditor of the company.

Additional details on the voting are set out herein.

Election of directors

A total of 383,458,757 votes, or approximately 99.99 per cent of the votes cast at the meeting, were cast in favour of the fixing the number of directors of the company at six.

The details of the proxy voting for the re-election of the six director nominees are set out in an attached table.

Appointment of auditor

A total of 383,435,323 votes, or approximately 99.98 per cent of the votes cast at the meeting, were cast in favour of appointing Deloitte as the new external auditor of the company, as the successor to the company's former auditor, PricewaterhouseCoopers LLP.

For more information on the resolutions and the business of the meeting, readers should refer to the circular, a copy of which is available under the company's profile on SEDAR+.

About Healwell AI Inc.

Healwell is a health care artificial intelligence company focused on preventative care. Its mission is to improve health care and save lives through the early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help health care providers detect rare and chronic diseases, improve efficiency of their practice and, ultimately, help improve patient health outcomes. Healwell is executing a strategy centred around developing and acquiring technology and clinical sciences capabilities that complement the company's road map.